[ad_1]
This British duo has overcome a major hurdle in the international competition for a safe and effective remedy since the creation of the new pandemic coronavirus.
A study published in the medical journal The Lancet confirms that the vaccine is effective by an average of 70%. cases. In patients who received two full doses of the vaccine, the effectiveness was 62 percent, while the effectiveness increased to 90 percent in the first half and in the second full dose.
These data are “the first comprehensive efficiencies published in the peer-reviewed journal [tyrimų] results’ for the COVID-19 vaccine, writes The Lancet.
The study was published after a series of events that raised hopes that vaccination could help control a pandemic that has already claimed more than 1.5 million lives around the world. lives.
Britain on Tuesday became the first Western country to launch an immunization program using a vaccine developed by Pfizer and BioNTech. This vaccine was approved for widespread use last week.
According to Andrew Pollard, director of the Oxford Vaccine Group (OVG) at the University of Oxford, a post in The Lancet shows that vaccine developers are “publishing data in a transparent way.”
According to him, several vaccines will be needed to control the pandemic, because “otherwise we will be in the same situation in six months.”
“It just came to our knowledge then [vakcinų] “It must be a competition with the virus,” he told a news conference.
AstraZeneca and the University of Oxford published an overview of the results last month with questions about their analysis, which used 23,000 jobs. data from individuals who participated in separate trials conducted under different protocols.
They were related to a smaller group whose members initially received half the dose of the vaccine by mistake.
Tuesday’s article confirms that there were no people over 55 in this group of 1,367 people.
According to the authors, they provided the Lancet reviewers with additional analysis that would show that the best results of the group of people vaccinated at half the initial dose did not depend on other factors such as age.
However, the authors indicated that more research will be needed.
AstraZeneca states that the supervisory authority should use this data to decide whether to vaccinate people with two full doses, or half the dose first and then the full dose.
“In my opinion, it would be fair to say that more studies are needed to explain these intriguing results,” Pollard said.
It confirmed that half of the starting dose was taken ‘unplanned’, that this was due to a discrepancy in the measurements, but that when the researchers noted an error, these cases were included in the trials with the consent of the supervisory authorities.
[ad_2]
